{"classes":[{"categories":[{"measurements":[{"comment":"Not evaluable due to insufficient number of events","groupId":"OG000","lowerLimit":"27.8","upperLimit":"NA","value":"35"},{"comment":"Not evaluable due to insufficient number of events","groupId":"OG001","lowerLimit":"30.7","upperLimit":"NA","value":"32"},{"comment":"Not evaluable due to insufficient number of events","groupId":"OG002","lowerLimit":"18.6","upperLimit":"NA","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"description":"OS is defined as the time from date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to 5.2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}